CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis

V Fridman, B Bundy, M M Reilly, D Pareyson, C Bacon, J Burns, J Day, S Feely, R S Finkel, T Grider, C A Kirk, D N Herrmann, M Laurá, J Li, T Lloyd, C J Sumner, F Muntoni, G Piscosquito, S Ramchandren, R Shy, C E Siskind, S W Yum, I Moroni, E Pagliano, S Zuchner, S S Scherer, M E Shy, Inherited Neuropathies Consortium, V Fridman, B Bundy, M M Reilly, D Pareyson, C Bacon, J Burns, J Day, S Feely, R S Finkel, T Grider, C A Kirk, D N Herrmann, M Laurá, J Li, T Lloyd, C J Sumner, F Muntoni, G Piscosquito, S Ramchandren, R Shy, C E Siskind, S W Yum, I Moroni, E Pagliano, S Zuchner, S S Scherer, M E Shy, Inherited Neuropathies Consortium

Abstract

Background: The international Inherited Neuropathy Consortium (INC) was created with the goal of obtaining much needed natural history data for patients with Charcot-Marie-Tooth (CMT) disease. We analysed clinical and genetic data from patients in the INC to determine the distribution of CMT subtypes and the clinical impairment associated with them.

Methods: We analysed data from 1652 patients evaluated at 13 INC centres. The distribution of CMT subtypes and pathogenic genetic mutations were determined. The disease burden of all the mutations was assessed by the CMT Neuropathy Score (CMTNS) and CMT Examination Score (CMTES).

Results: 997 of the 1652 patients (60.4%) received a genetic diagnosis. The most common CMT subtypes were CMT1A/PMP22 duplication, CMT1X/GJB1 mutation, CMT2A/MFN2 mutation, CMT1B/MPZ mutation, and hereditary neuropathy with liability to pressure palsy/PMP22 deletion. These five subtypes of CMT accounted for 89.2% of all genetically confirmed mutations. Mean CMTNS for some but not all subtypes were similar to those previously reported.

Conclusions: Our findings confirm that large numbers of patients with a representative variety of CMT subtypes have been enrolled and that the frequency of achieving a molecular diagnosis and distribution of the CMT subtypes reflects those previously reported. Measures of severity are similar, though not identical, to results from smaller series. This study confirms that it is possible to assess patients in a uniform way between international centres, which is critical for the planned natural history study and future clinical trials. These data will provide a representative baseline for longitudinal studies of CMT.

Clinical trial registration: ID number NCT01193075.

Keywords: GENETICS; NEUROGENETICS; NEUROPATHY.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Figures

Figure 1
Figure 1
Distribution of clinically determined Charcot-Marie-Tooth (CMT) subtypes.

References

    1. Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clin Genet 1974;6:98–118.
    1. Rossor AM, Polke JM, Houlden H, et al. . Clinical implications of genetic advances in Charcot-Marie-Tooth disease. Nat Rev Neurol 2013;9:562–71.
    1. Shy ME, Blake J, Krajewski K, et al. . Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology 2005;64:1209–14.
    1. Shy ME, Chen L, Swan ER, et al. . Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology 2008;70:378–83.
    1. Pareyson D, Reilly MM, Schenone A, et al. . Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol 2011;10:320–8.
    1. Lewis RA, McDermott MP, Herrmann DN, et al. . High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial. JAMA Neurol 2013;70:981–7.
    1. Shy ME, Siskind C, Swan ER, et al. . CMT1X phenotypes represent loss of GJB1 gene function. Neurology 2007;68:849–55.
    1. Feely SM, Laura M, Siskind CE, et al. . MFN2 mutations cause severe phenotypes in most patients with CMT2A. Neurology 2011;76:1690–6.
    1. Shy ME, Jani A, Krajewski K, et al. . Phenotypic clustering in MPZ mutations. Brain 2004;127:371–84.
    1. Saporta AS, Sottile SL, Miller LJ, et al. . Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol 2011;69:22–33.
    1. Lupski JR, de Oca-Luna RM, Slaugenhaupt S, et al. . DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 1991;66:219–32.
    1. Timmerman V, Nelis E, Van Hul W, et al. . The peripheral myelin protein gene PMP-22 is contained within the Charcot-Marie-Tooth disease type 1A duplication. Nat Genet 1992;1:171–5.
    1. Shy M, Lupski JR, Chance PF, et al. . The hereditary motor and sensory neuropathies: an overview of the clinical, genetic, electrophysiologic and pathologic features. In: Dyck PJ. TP, ed. Peripheral neuropathy. 4th ed. Philadelphia: WB Saunders, 2005:1623–58.
    1. Murphy SM, Laura M, Fawcett K, et al. . Charcot-Marie-Tooth disease: frequency of genetic subtypes and guidelines for genetic testing. J Neurol Neurosurg Psychiatry 2012;83:706–10.
    1. Latour P, Gonnaud PM, Ollagnon E, et al. . SIMPLE mutation analysis in dominant demyelinating Charcot-Marie-Tooth disease: three novel mutations. J Peripher Nerv Syst 2006;11:148–55.
    1. Gess B, Schirmacher A, Boentert M, et al. . Charcot-Marie-Tooth disease: frequency of genetic subtypes in a German neuromuscular center population. Neuromuscul Disord 2013;23:647–51.
    1. Murphy SM, Laura M, Reilly MM. DNA testing in hereditary neuropathies. Handb Clin Neurol 2013;115:213–32.
    1. Karadima G, Floroskufi P, Koutsis G, et al. . Mutational analysis of PMP22, GJB1 and MPZ in Greek Charcot-Marie-Tooth type 1 neuropathy patients. Clin Genet 2011;80:497–9.
    1. Braathen G, Sand J, Lobato A, et al. . Genetic epidemiology of Charcot-Marie-Tooth in the general population. Eur J Neurol 2011;18:39–48.
    1. Sivera R, Sevilla T, Vilchez JJ, et al. . Charcot-Marie-Tooth disease: genetic and clinical spectrum in a Spanish clinical series. Neurology 2013;81: 1617–25.
    1. Abe A, Numakura C, Kijima K, et al. . Molecular diagnosis and clinical onset of Charcot-Marie-Tooth disease in Japan. J Hum Genet 2011;56:364–8.
    1. Birouk N. [Charcot-Marie-Tooth disease]. Presse Med 2009;38: 200–9.
    1. Murphy SM, Herrmann DN, McDermott MP, et al. . Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease. J Peripher Nerv Syst 2011;16:191–8.
    1. Tousignant R, Trepanier A, Shy ME, et al. . Genetic testing practices for Charcot-Marie-Tooth type 1A disease. Muscle Nerve 2014;49: 478–82.
    1. Sadjadi R, Shy M, Reilly M, et al. . Psychometric evaluation of Charcot-Marie-Tooth disease (CMT) neuropathy score CMTNS) version 2.0 using Rasch analysis (Abstract). J Peripher Nerv Syst 2014. Nov 14. doi:10.1111/jns.12084
    1. Burns J, Ouvrier R, Estilow T, et al. . Validation of the Charcot-Marie-Tooth disease pediatric scale as an outcome measure of disability. Ann Neurol 2012;71: 642–52.
    1. Ramchandren S, Shy M, Feldman E, et al. . Defining disability: patient and health care provider perspectives in Charcot Marie Tooth disease. J Neurol Neurosurg Psychiatry 2015;86:635–9..
    1. Thomas PK, Marques W, Davis MB, et al. . The phenotypic manifestations of chromosome 17p11.2 duplication. Brain 1997;120:465–78.
    1. Scherer SS, Kleopa KA. X-linked Charcot-Marie-Tooth disease. J Peripher Nerv Syst 2012;17(Suppl 3):9–13.
    1. Siskind CE, Murphy SM, Ovens R, et al. . Phenotype expression in women with CMT1X. J Peripher Nerv Syst 2011;16:102–7.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться